From reading the web articles I mainly see it is a revalidation of the pre-clinical work that was done in the 1980s - particularly for AML and Breast Cancer. Although the recent study does emphasise the strength / potency of Bisantrene as an anti-cancer agent in both AML and solid tumors.
So in general we have the Israel trial validating the historic in-human trials in a modern context and this study validating the historic preclinical work in a modern context.
I guess at some point RAC will announce results from their pre-clinical breast cancer work. We haven't seen anything announced yet about their preclinical AML work.
RAC Charts, page-1444
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.58 |
Change
0.055(3.62%) |
Mkt cap ! $268.4M | |||
| Open | High | Low | Value | Volume |
| $1.56 | $1.61 | $1.56 | $106.0K | 67.13K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 649 | $1.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 3000 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |